Frontiers in Pharmacology, Год журнала: 2025, Номер 16

Опубликована: Апрель 1, 2025

Colorectal cancer (CRC) is a common and aggressive malignancy with the complex varied molecular landscape. Mitochondria play pivotal role in metabolic reprogramming of cells, their function can profoundly influence tumor progression. Therefore, identifying mitochondrial genes immune-related features may offer promising new approach for prognosis CRC. Mitochondrial-associated were retrieved from MITOCARTA 3.0 dataset. The LASSO regression method was applied to identify prognostic genes, while area under ROC curve nomograms used assess robustness model. Single-sample genomic enrichment analysis (ssGSEA) utilized explore relationship between model immune infiltration, drug sensitivity conducted potential therapeutic agents. Cellular assays performed validate effectiveness identified drugs. Key including SUCLG2, ACACB, OSBPL1A, TRAP1, have been as significant markers expression ACACB OSBPL1A progressively increased, SUCLG2 TRAP1 decreased patients. TCGA dataset showed an (AUC) greater than 0.6 1-, 2-, 3-year survival predictions, demonstrating strong this Additionally, strongly correlated particularly CD8 + T checkpoint regulators. Molecular docking revealed that binds dabrafenib at glycine position 747. confirmed effectively inhibited CRC cell migration proliferation, providing avenue. Our findings suggested four mitochondrial-related study provide accurate predictions

Язык: Английский